Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 53, 2023 - Issue 5
168
Views
0
CrossRef citations to date
0
Altmetric
General Xenobiochemistry

The influence of temperature on the metabolic activity of CYP2C9, CYP2C19, and CYP3A4 genetic variants in vitro

, , , , , , , ORCID Icon, , , , & show all
Pages 357-365 | Received 16 Apr 2023, Accepted 12 Aug 2023, Published online: 23 Aug 2023

References

  • Anderson KB, Poloyac SM, Kochanek PM, Empey PE. 2016. Effect of hypothermia and targeted temperature management on drug disposition and response following cardiac arrest: a comprehensive review of preclinical and clinical investigations. Ther Hypothermia Temp Manag. 6(4):169–179. doi: 10.1089/ther.2016.0003.
  • Carney N, Totten AM, O'Reilly C, Ullman JS, Hawryluk GW, Bell MJ, Bratton SL, Chesnut R, Harris OA, Kissoon N, et al. 2017. Guidelines for the management of severe traumatic brain injury, fourth edition. Neurosurgery. 80(1):6–15. doi: 10.1227/NEU.0000000000001432.
  • Chiba K. 1998. Genetic polymorphism of the CYP2C subfamily. Nihon Yakurigaku Zasshi. 112(1):15–21. doi: 10.1254/fpj.112.15.
  • Empey PE, Miller TM, Philbrick AH, Melick JA, Kochanek PM, Poloyac SM. 2012. Mild hypothermia decreases fentanyl and midazolam steady-state clearance in a rat model of cardiac arrest. Crit Care Med. 40(4):1221–1228. doi: 10.1097/CCM.0b013e31823779f9.
  • Empey PE, Velez de Mendizabal N, Bell MJ, Bies RR, Anderson KB, Kochanek PM, Adelson PD, Poloyac SM, 2013. Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury. Crit Care Med. 41(10):2379–2387. doi: 10.1097/CCM.0b013e318292316c.
  • Gillam EMJ, Baba T, Kim BR, Ohmori S, Guengerich FP. 1993. Expression of modified human cytochrome P450 3A4 in Esherichia coli and purification and reconstitution of the enzyme. Arch Biochem Biophys. 305(1):123–131. doi: 10.1006/abbi.1993.1401.
  • Iwata H, Fujita K, Kushida H, Suzuki A, Konno Y, Nakamura K, Fujino A, Kamataki T. 1998. High catalytic activity of human cytochrome P450 Co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochem Pharmacol. 55(8):1315–1325. doi: 10.1016/s0006-2952(97)00643-6.
  • Lau PS, Leong KVG, Ong CE, Dong ANHM, Pan Y. 2017. In vitro functional characterisation of cytochrome P450 (CYP) 2C19 allelic variants CYP2C19*23 and CYP2C19*24. Biochem Genet. 55(1):48–62. doi: 10.1007/s10528-016-9771-8.
  • Lewis DF. 1998. The CYP2 family: models, mutants and interactions. Xenobiotica. 28(7):617–661. doi: 10.1080/004982598239236.
  • Li X, Ji Z, Gu Y, Hu Y, Huang K, Pan S. 2016. Mild hypothermia decreases the total clearance of glibenclamide after low dose administration in rats. Neurosci Lett. 614:55–59. doi: 10.1016/j.neulet.2015.12.035.
  • Lin JH, Lu AY. 2001. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol. 41:535–567. doi: 10.1146/annurev.pharmtox.41.1.535.
  • Miyamoto H, Matsueda S, Moritsuka A, Shimokawa K, Hirata H, Nakashima M, Sasaki H, Fumoto S, Nishida K. 2015. Evaluation of hypothermia on the in vitro metabolism and binding and in vivo disposition of midazolam in rats. Biopharm Drug Dispos. 36(7):481–489. doi: 10.1002/bdd.1960.
  • Miyazaki M, Nakamura K, Fujita Y, Guengerich FP, Horiuchi R, Yamamoto K. 2008. Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone. Drug Metab Dispos. 36(11):2287–2291. doi: 10.1124/dmd.108.021816.
  • Mody P, Kulkarni N, Khera R, Link MS. 2019. Targeted temperature management for cardiac arrest. Prog Cardiovasc Dis. 62(3):272–278.; doi: 10.1016/j.pcad.2019.05.007.
  • Murayama N, Nakamura T, Saeki M, Soyama A, Saito Y, Sai K, Ishida S, Nakajima O, Itoda M, Ohno Y, et al. 2002. CYP3A4 gene polymorphisms influence teststerone 6β-hydroxylation. Drug Metab Pharmacokinet. 17(2):150–156. doi: 10.2133/dmpk.17.150.
  • Omura T, Sato R. 1964. The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem. 239(7):2379–2385. doi: 10.1016/S0021-9258(20)82245-5.
  • PharmVar. https://www.pharmvar.org/gene/CYP2C19. last accessed: 2023/3/06
  • Poppe M, Clodi C, Schriefl C, Mueller M, Sunder-Plaßmann R, Reiter B, Rechenmacher M, van Os W, van Hasselt JGC, Holzer M, et al. 2022. Targeted temperature management after cardiac arrest is associated with reduced metabolism of pantoprazole - A probe drug of CYP2C19 metabolism. Biomed Pharmacother. 146:112573. Feb; doi: 10.1016/j.biopha.2021.112573.
  • Razavi BS, Blagodatskaya E, Kuzyakov Y. 2015. Nonlinear temperature sensitivity of enzyme kinetics explains canceling effect-a case study on loamy haplic Luvisol. Front Microbiol. 6:1126. doi: 10.3389/fmicb.2015.01126.
  • Sano E, Li W, Yuki H, Liu X, Furihata T, Kobayashi K, Chiba K, Neya S, Hoshino T. 2010. Mechanism of the decrease in catalytic activity of human cytochrome P450 2C9 polymorphic variants investigated by computational analysis. J Comput Chem. 31(15):2746–2758. doi: 10.1002/jcc.21568.
  • Shedlofsky SI, Israel BC, McClain CJ, Hill DB, Blouin RA. 1994. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest. 94(6):2209–2214. doi: 10.1172/JCI117582.
  • Soons PA, Grib C, Breimer DD, Kirch W. 1992. Effects of acute febrile infectious diseases on the oral pharmacokinetics and effects of nitrendipine enantiomers and of bisoprolol. Clin Pharmacokinet. 23(3):238–248. doi: 10.2165/00003088-199223030-00006.
  • Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. 1996. The role of the CYP2C9 Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 6(4):341–349. doi: 10.1097/00008571-199608000-00007.
  • Takahashi M, Saito T, Ito M, Tsukada C, Katono Y, Hosono H, Maekawa M, Shimada M, Mano N, Oda A, et al. 2015. Functional characterization of 21 CYP2C19 allelic variants for clopidogrel 2-oxidation. Pharmacogenomics J. 15(1):26–32. doi: 10.1038/tpj.2014.30.
  • Wang H, An N, Wang H, Gao Y, Liu D, Bian T, Zhu J, Chen C. 2011. Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-Mephenytoin 4-hydroxylation and omeprazole 5-Hydroxylation. Drug Metab Dispos. 39(5):830–837. doi: 10.1124/dmd.110.037549.
  • Yamaguchi Y, Akiyoshi T, Kawamura G, Imaoka A, Miyazaki M, Guengerich FP, Nakamura K, Yamamoto K, Ohtani H. 2021. Comparison of the inhibitory effects of azole antifungals on cytochrome P450 3A4 genetic variants. Drug Metab Pharmacokinet. 38:100384.; doi: 10.1016/j.dmpk.2021.100384.
  • Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. 1981. A pharmacokinetic analysis program (multi) for microcomputer. Journal of Pharmacobio-Dynamics. 4(11):879–885. doi: 10.1248/bpb1978.4.879.
  • Zanger UM, Schwab M. 2013. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 138(1):103–141. doi: 10.1016/j.pharmthera.2012.12.007.
  • Zhou SF, Liu JP, Chowbay B. 2009. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 41(2):89–295. doi: 10.1080/03602530902843483.
  • Zhou X-Y, Hu X-X, Li M-F, Wang H, Zhang L-Q, Hu G-X, Cai J-P. 2018. Functional characterization of CYP2C19 variants in nebivolol 4-hydroxlation in vitro. Drug Test Anal. 10(5):807–813. doi: 10.1002/dta.2334.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.